Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Monoclonal antibodies as an addition to current myeloma therapy strategies.

Expert review of anticancer therapy·2020

Same author

Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials.

European journal of nuclear medicine and molecular imaging·2020

Same author

Antithymocyte globulin administration in patients with profound lymphopenia receiving a PBSC purine analog/busulfan-based conditioning regimen allograft.

Scientific reports·2020

Same author

Glucose Metabolism Quantified by SUVmax on Baseline FDG-PET/CT Predicts Survival in Newly Diagnosed Multiple Myeloma Patients: Combined Harmonized Analysis of Two Prospective Phase III Trials.

Cancers·2020

Same author

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse.

Leukemia·2020

Same author

Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study.

Blood cancer journal·2020

Same journal

Are electrical stimulation devices the way forward for addressing heavy menstrual bleeding in women with von Willebrand disease?

Expert review of hematology·2026

Same journal

Embedding cardiovascular risk assessment into routine BTK inhibitor management in chronic lymphocytic leukemia.

Expert review of hematology·2026

Same journal

The impact of a cancer diagnosis for myeloproliferative neoplasm (MPN) patients.

Expert review of hematology·2026

Same journal

Lessons from warfarin management during the COVID-19 pandemic: from crisis to an opportunity to revolutionize telemedicine for chronic disease care.

Expert review of hematology·2026

Same journal

Efficacy of pacritinib versus momelotinib in patients with thrombocytopenic myelofibrosis: a matching-adjusted indirect treatment comparison.

Expert review of hematology·2026

Same journal

Prognostic factors for patients with relapsed or refractory multiple myeloma who are initiating a fourth or later line car T-cell or bispecific antibody therapy: a systematic literature review and meta-analysis.

Expert review of hematology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 6, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Communications on multiple myeloma.

Philippe Moreau¹

¹Hematology Department, University Hospital Hôtel-Dieu, Place Ricordeau, 44093 Nantes, France. philippe.moreau@chu-nantes.fr

Expert Review of Hematology

|November 19, 2010

Summary

This summary is machine-generated.

New hematology drugs and treatments for all age groups were presented at the 50th American Society of Hematology meeting. Key findings included novel therapies and combination treatments for diverse patient populations.

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Related Experiment Videos

Last Updated: Jun 6, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Area of Science:

Hematology
Oncology
Internal Medicine

Background:

The 50th annual meeting of the American Society of Hematology convened to discuss advancements in blood disorder research.
Focus areas included novel therapeutic agents, patient-specific treatment strategies, and innovative combination therapies.

Framework:

The report synthesizes key data from nine pivotal presentations.
Emphasis is placed on recent clinical trial outcomes and emerging treatment paradigms.

Implementation:

Discussion covers the application of new drugs in hematological malignancies.
Treatment approaches for patients across the age spectrum (pediatric, adult, and geriatric) were detailed.
The efficacy of novel drug combinations was a significant topic.

Implications:

These advancements promise to reshape the therapeutic landscape for various hematologic conditions.
Future research directions and clinical practice guidelines may be influenced by these findings.
Optimized treatment strategies are expected to improve patient outcomes and quality of life.